Drug-induced mitochondrial toxicity

Archive ouverte

Massart, J. | Borgne-Sanchez, A. | Fromenty, B.

Edité par CCSD ; Springer International Publishing -

International audience. Mitochondrial dysfunction can be a major mechanism whereby different drugs can induce adverse effects affecting different tissues such as liver, heart and skeletal muscle. In the most severe cases, drug-induced mitochondrial dysfunction can require a hospitalization, or lead to the death of the patient. Moreover, these adverse effects can lead to the withdrawal of drugs from the market, or earlier during clinical trials. Drugs can induce mitochondrial dysfunction by different mechanisms including inhibition of fatty acid oxidation, impairment of oxidative phosphorylation and respiratory chain activity as well as alteration of the integrity of the mitochondrial membranes. Some drugs also impair mitochondrial function via the production of reactive oxygen species and the generation of reactive metabolites, which can covalently bind to key mitochondrial proteins. The present chapter focuses on different drugs for which enough clinical and experimental evidence indicates the potential role of mitochondrial dysfunction in the pathogenesis of adverse effects such as liver injury, myopathy and cardiotoxicity acetaminophen, amiodarone, doxorubicin, nucleoside reverse transcriptase inhibitors (e.g. stavudine, zidovudine, didanosine), statins (e.g. atorvastatin, cerivastatin, simvastatin) and valproic acid. Notably, these drugs epitomize the diversity of the mechanisms whereby xenobiotics can induce mitochondrial dysfunction and also the variety of the targeted tissues. Other drugs affecting mitochondrial function by similar mechanisms are discussed more briefly in the present chapter. Because drug-induced mitochondrial dysfunction and related adverse events are major issues for public health and pharmaceutical companies, mitochondrial liability should be systematically investigated during preclinical safety studies. © Springer International Publishing AG, part of Springer Nature 2018.

Consulter en ligne

Suggestions

Du même auteur

3D multi-cell-type liver organoids: A new model of non-alcoholic fatty liver disease for drug safety assessments

Archive ouverte | Bronsard, J. | CCSD

International audience. The development of in vitro models that recapitulate critical liver functions is essential for accurate assessments of drug toxicity. Although liver organoids can be used for drug discovery a...

Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease

Archive ouverte | Massart, J. | CCSD

International audience. Metabolic-associated fatty liver disease (MAFLD), which is often linked to obesity, en-compasses a large spectrum of hepatic lesions, including simple fatty liver, steatohepatitis, cirrhosis ...

Mitochondrial dysfunction induced by xenobiotics Involvement in steatosis and steatohepatitis

Archive ouverte | Begriche, K. | CCSD

International audience. Many xenobiotics are able to induce liver steatosis, also referred to as fatty liver. This liver lesion is benign, but it can progress in the long term to steatohepatitis characterized by nec...

Chargement des enrichissements...